The "identikit" of subject with obesity and COVID-19 vaccine breakthrough.
COVID-19
SARS-CoV-2
hypertension
obesity
type 2 diabetes
vaccine breakthrough
Journal
EXCLI journal
ISSN: 1611-2156
Titre abrégé: EXCLI J
Pays: Germany
ID NLM: 101299402
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
03
2022
accepted:
06
04
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
The mRNA coronavirus disease 2019 (COVID-19) vaccines were highly effective in the prevention of symptomatic COVID-19, hospitalization, severe disease, and death. However, a minority of vaccinated individuals might become infected and experience significant morbidity. Risk factors of COVID-19 vaccine breakthrough in obesity have not been elucidated. Thus, we aimed to portray the subjects with obesity developing COVID-19 vaccine breakthrough despite vaccination. Coronavirus 2019 (COVID-19) mRNA vaccines have been highly effective in preventing symptomatic COVID-19, hospitalization, severe illness and death. However, a minority of vaccinated individuals may become infected and experience considerable morbidity. The risk factors for COVID-19 vaccine breakthrough in obesity have not been elucidated. Therefore, we aimed to depict individuals with obesity who develop COVID-19 vaccine breakthrough despite vaccination. An online questionnaire was distributed to respondents via a snowball sampling method among subjects with obesity belonging to Italian Associations for people living with obesity aged 18 years and above. Two hundred and thirty-five respondents (44.5±14 years; BMI: 33.3±7.2 kg/m
Identifiants
pubmed: 35721580
doi: 10.17179/excli2022-4864
pii: 2022-4864
pmc: PMC9203987
doi:
Types de publication
Journal Article
Langues
eng
Pagination
687-694Informations de copyright
Copyright © 2022 Muscogiuri et al.
Références
Lancet Infect Dis. 2021 Nov;21(11):1485-1486
pubmed: 34506735
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Cell Metab. 2018 Dec 4;28(6):922-934.e4
pubmed: 30174303
Obes Rev. 2021 Jun;22(6):e13216
pubmed: 33719175
Metabolism. 2020 Jul;108:154251
pubmed: 32353356
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Inflammopharmacology. 2021 Oct;29(5):1357-1360
pubmed: 34279767
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675
Obes Rev. 2015 Dec;16(12):1017-29
pubmed: 26354800
Endocrine. 2021 May;72(2):317-325
pubmed: 33886062
Adv Nutr. 2016 Jan 15;7(1):66-75
pubmed: 26773015
Cell Metab. 2020 Sep 1;32(3):437-446.e5
pubmed: 32697943
Vaccine. 2015 Aug 26;33(36):4422-9
pubmed: 26163925
J Obes. 2021 Jan 22;2021:8837319
pubmed: 33542836
Diabetes Metab Res Rev. 2022 Jan;38(1):e3465
pubmed: 33955644
Nat Rev Endocrinol. 2021 Mar;17(3):135-149
pubmed: 33479538
Molecules. 2020 Dec 23;26(1):
pubmed: 33374759
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
Int J Obes (Lond). 2017 Sep;41(9):1324-1330
pubmed: 28584297
Int J Obes (Lond). 2022 Mar;46(3):449-465
pubmed: 35058571
Respir Med. 2021 Mar;178:106322
pubmed: 33550151
Clin Microbiol Infect. 2021 Nov;27(11):1652-1657
pubmed: 34245907
Diabetes. 2021 Dec;70(12):2745-2755
pubmed: 34615619
Ir J Med Sci. 2021 Aug;190(3):1237-1238
pubmed: 33068241